Skip to content

Application of Remote Ischemic Preconditioning in Patients Undergoing Open Heart Surgeries

Evaluation of Remote Preconditioning on Heart Resistance to Ischemia and Reperfusion Injury

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01906918
Enrollment
120
Registered
2013-07-24
Start date
2013-08-31
Completion date
2015-08-31
Last updated
2013-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Valvular Heart Disease

Keywords

ischemia, reperfusion, myocardial ischemia, myocardial reperfusion

Brief summary

Strategies for myocardial protection during open heart surgeries are desired. Several experimental studies have shown beneficial effects of remote ischemic preconditioning (RIPC). The underlying mechanisms are not totally understood. This study intends to evaluate molecular mechanisms involved with RIPC on myocardium of patients underwent open heart surgeries.

Interventions

PROCEDUREIRPC, Remote preconditioning

The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.

Sponsors

University of Campinas, Brazil
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Patients older than 18 years * Scheduled for coronary artery bypass grafting with or without valve replacement associated * Use of blood cardioplegia * EuroSCORE II greater than or equal to 1.0%

Exclusion criteria

* History of cardiogenic shock * Complications in the admission * Pregnant patients * Severe peripheral arterial disease affecting the upper limbs * Liver failure (bilirubin ˃ 20 mmol / L, INR 2.0 ˃) * Significant pulmonary disease (˂ FEV1 40%) * Renal failure with glomerular filtration rate ˂ ml/min/1,73 m² * Concomitant treatment with glibenclamide or nicorandil (medications that interfere with cardioprotection induced by IPCR)

Design outcomes

Primary

MeasureTime frame
Molecular pathway activation2 days
Inflammatory response10 days

Secondary

MeasureTime frame
All cause of mortality30 days

Countries

Brazil

Contacts

Primary ContactOrlando Petrucci, MD, PhD
petrucci@cardiol.br+55 19 97253335

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026